Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The restructuring leaves oncology and IDEC behind and reemphasizes the "Biogen" in Biogen Idec.
You may also be interested in...
Biogen Begins Its Oncology Sell-Off, Parting With Two Kinase Inhibitors
New CEO George Scangos pledged in November to return Biogen Idec to its neurology and immunology roots. This is the first divestment deal under the new regime.
Biogen Begins Its Oncology Sell-Off, Parting With Two Kinase Inhibitors
New CEO George Scangos pledged in November to return Biogen Idec to its neurology and immunology roots. This is the first divestment deal under the new regime.
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.